Pelthos Therapeutics Inc PTHS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $27.16
- Day Range
- $26.55–27.65
- 52-Week Range
- $0.00–37.50
- Bid/Ask
- $22.81 / $43.76
- Shares Outstanding
- 3.48M
- Market Cap
- $92.28M
- Volume/Avg
- 29,776 / 22,061
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 92
- Website
- https://www.pelthos.com
Valuation
|
Metric
|
PTHS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.36 |
Price/Sales | 2.27 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PTHS
|
|---|---|
Quick Ratio | 1.75 |
Current Ratio | 2.79 |
Interest Coverage | −10.27 |
Quick Ratio
PTHS
Profitability
|
Metric
|
PTHS
|
|---|---|
Return on Assets (Normalized) | −56.10% |
Return on Equity (Normalized) | −186.43% |
Return on Invested Capital (Normalized) | −106.54% |
Return on Assets
PTHS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<<vPf^ | LOCK|>d$< | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|HxFt!@ | LOCK|Htdrs | $70B | |||
| argenx SE ADR
ARGX
| LOCK|JQ@&DB% | LOCK|xXK | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>^Z?#cq | LOCK|^S@%G | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|DC@@D#m | LOCK|KK | $36B | |||
| Moderna Inc
MRNA
| LOCK|WjQ^p! | LOCK|cC@ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%lgQQ>%$ | LOCK|T>x?q | $25B | |||
| Incyte Corp
INCY
| LOCK|&tHP%qf | LOCK|ZZ% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Qcd^#% | LOCK|#<B | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|S@!g#^ | LOCK|y>t | $17B |
United States